# Subtype-specific NK cell-TAM interactions drive a novel prognostic signature in HNSCC

**Authors:** Zhenyan Zhao, Xuejiao Han, Yating Hu, Yun Li, Yaodong He, Yan Wang, Yanbing Yao, Huan Li, Jianhua Wei

PMC · DOI: 10.3389/fimmu.2025.1676878 · 2025-10-17

## TL;DR

This study explores how different types of immune cells interact in head and neck cancer, revealing a new tool to predict patient outcomes and treatment response.

## Contribution

The study introduces a novel 23-gene signature (CINT) based on subtype-specific NK-TAM interactions for HNSCC prognosis and immunotherapy prediction.

## Key findings

- IL32+NK cells interact strongly with APOE+TAM and CXCL10+TAM via specific pathways.
- The CINT signature effectively stratifies patient risk and predicts survival benefit in immunotherapy.
- High CD16/CD64 expression correlates with better prognosis, while CD163 indicates worse outcomes.

## Abstract

The immune microenvironment of head and neck squamous cell carcinoma (HNSCC) is highly complex, and the mechanisms underlying interactions between natural killer (NK) cells and tumor-associated macrophages (TAMs) remain unclear. This study investigates the cellular heterogeneity, interaction patterns, and prognostic significance of NK-TAM crosstalk through multi-omics analyses.

A total of 58 HNSCC tissue samples were analyzed. NK and TAM subsets were identified using immunohistochemistry (CD16, CD64, CD163), single-cell RNA sequencing (GSE139324), and public databases (TCGA-HNSC, GSE65858). CellChat was used to infer ligand-receptor interactions, while spatial proximity was assessed via the CSOmap algorithm and validated by immunofluorescence. A prognostic model was constructed using LASSO Cox regression and validated in an immunotherapy cohort (PRJEB23709, phs000452.v2.p1).

High CD16/CD64 expression correlated with favorable prognosis, while CD163 indicated poor outcomes (P < 0.05). NK cells were divided into IL32+NK (antiviral, T cell–activating), NFKBIA+NK (ribosome-related), and STMN1+NK (DNA repair–related) subsets. TAMs included APOE+TAM (M2-like), IL1B+/CXCL10+TAM (M1-like), and HSP+TAM (stress-responsive). IL32+NK interacted most strongly with APOE+TAM and CXCL10+TAM via SPP1, MIF, and ITGB2 pathways. Spatial mapping and immunofluorescence confirmed proximity and a positive correlation between IL32 and CXCL10 (R = 0.641, P < 0.001), and a negative correlation with APOE (R=–0.686, P < 0.001). A 23-gene NK-TAM interaction–related signature (CINT) effectively stratified patient risk in both training and validation cohorts (P < 0.05) and predicted survival benefit in immunotherapy-treated patients.

This study uncovers subtype-specific NK-TAM interactions in HNSCC and introduces CINT as a robust prognostic and immunotherapy response model, offering a new strategy for immune microenvironment–targeted therapy.

## Linked entities

- **Genes:** FCGR3B (Fc gamma receptor IIIb) [NCBI Gene 2215], FCGR1A (Fc gamma receptor Ia) [NCBI Gene 2209], CD163 (CD163 molecule) [NCBI Gene 9332], IL32 (interleukin 32) [NCBI Gene 9235], NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792], STMN1 (stathmin 1) [NCBI Gene 3925], APOE (apolipoprotein E) [NCBI Gene 348], IL1B (interleukin 1 beta) [NCBI Gene 3553], CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627], HSP90B2P (heat shock protein 90 beta family member 2, pseudogene) [NCBI Gene 7190], SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696], MIF (macrophage migration inhibitory factor) [NCBI Gene 4282], ITGB2 (integrin subunit beta 2) [NCBI Gene 3689]
- **Diseases:** head and neck squamous cell carcinoma (MONDO:0010150), HNSCC (MONDO:0010150)

## Full-text entities

- **Genes:** FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, STMN1 (stathmin 1) [NCBI Gene 3925] {aka C1orf215, LAP18, Lag, OP18, PP17, PP19}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, ITGB2 (integrin subunit beta 2) [NCBI Gene 3689] {aka CD18, LAD, LCAMB, LFA-1, MAC-1, MF17}, MIF (macrophage migration inhibitory factor) [NCBI Gene 4282] {aka GIF, GLIF, MMIF}, IL32 (interleukin 32) [NCBI Gene 9235] {aka IL-32alpha, IL-32beta, IL-32delta, IL-32gamma, NK4, TAIF}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, FCGR1A (Fc gamma receptor Ia) [NCBI Gene 2209] {aka CD64, CD64A, FCG1, FCGR1, FCRI, FcgammaRI}
- **Diseases:** HNSCC (MESH:D000077195), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12575298/full.md

---
Source: https://tomesphere.com/paper/PMC12575298